UBS Group’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $842K | Buy |
136,840
+69,499
| +103% | +$495K | ﹤0.01% | 5684 |
|
|
2025
Q4 | $486K | Buy |
67,341
+57,393
| +577% | +$464K | ﹤0.01% | 6099 |
|
|
2025
Q3 | $102K | Sell |
9,948
-3,258
| -25% | -$36.6K | ﹤0.01% | 7116 |
|
|
2025
Q2 | $137K | Sell |
13,206
-17,912
| -58% | -$191K | ﹤0.01% | 6981 |
|
|
2025
Q1 | $410K | Buy |
31,118
+13,538
| +77% | +$242K | ﹤0.01% | 6010 |
|
|
2024
Q4 | $315K | Buy |
17,580
+12,241
| +229% | +$248K | ﹤0.01% | 6174 |
|
|
2024
Q3 | $86.1K | Buy |
5,339
+3,102
| +139% | +$48.5K | ﹤0.01% | 6462 |
|
|
2024
Q2 | $60.4K | Sell |
2,237
-1,677
| -43% | -$40K | ﹤0.01% | 6542 |
|
|
2024
Q1 | $76.3K | Sell |
3,914
-478
| -11% | -$10.1K | ﹤0.01% | 6334 |
|
|
2023
Q4 | $90.8K | Buy |
4,392
+2,382
| +119% | +$71.1K | ﹤0.01% | 6223 |
|
|
2023
Q3 | $63.9K | Sell |
2,010
-110
| -5% | -$3.67K | ﹤0.01% | 6128 |
|
|
2023
Q2 | $71.2K | Buy |
+2,120
| New | +$75.9K | ﹤0.01% | 6257 |
|
|
2022
Q4 | – | Sell |
-370
| Closed | -$18K | – | 11069 |
|
|
2022
Q3 | $18K | Buy |
+370
| New | +$20.3K | ﹤0.01% | 7536 |
|
|
2022
Q2 | – | Sell |
-39
| Closed | -$1K | – | 10837 |
|
|
2022
Q1 | $1K | Sell |
39
-804
| -95% | -$50.3K | ﹤0.01% | 9912 |
|
|
2021
Q4 | $82K | Sell |
843
-4,145
| -83% | -$446K | ﹤0.01% | 6485 |
|
|
2021
Q3 | $622K | Buy |
4,988
+4,797
| +2,512% | +$579K | ﹤0.01% | 4570 |
|
|
2021
Q2 | $24K | Sell |
191
-9,736
| -98% | -$1.16M | ﹤0.01% | 7148 |
|
|
2021
Q1 | $1.35M | Buy |
9,927
+9,924
| +330,800% | +$1.23M | ﹤0.01% | 3950 |
|
|
2020
Q4 | $0 | Sell |
3
-10
| -77% | -$867 | ﹤0.01% | 8690 |
|
|
2020
Q3 | $1K | Sell |
13
-1,049
| -99% | -$80.4K | ﹤0.01% | 7826 |
|
|
2020
Q2 | $91K | Buy |
+1,062
| New | +$96.3K | ﹤0.01% | 5373 |
|
|
2019
Q4 | – | Sell |
-130
| Closed | -$7K | – | 8353 |
|
|
2019
Q3 | $7K | Buy |
130
+129
| +12,900% | +$6.86K | ﹤0.01% | 7348 |
|
|
2019
Q2 | $0 | Sell |
1
-3
| -75% | -$204 | ﹤0.01% | 8111 |
|
|
2019
Q1 | $0 | Sell |
4
-361
| -99% | -$22.9K | ﹤0.01% | 8093 |
|
|
2018
Q4 | $29K | Buy |
365
+93
| +34% | +$21.2K | ﹤0.01% | 6510 |
|
|
2018
Q3 | $126K | Buy |
272
+152
| +127% | +$61.1K | ﹤0.01% | 5386 |
|
|
2018
Q2 | $48K | Buy |
120
+26
| +28% | +$9.22K | ﹤0.01% | 5992 |
|
|
2018
Q1 | $29K | Sell |
94
-11
| -10% | -$3.13K | ﹤0.01% | 6120 |
|
|
2017
Q4 | $31K | Buy |
105
+14
| +15% | +$6.12K | ﹤0.01% | 6205 |
|
|
2017
Q3 | $50K | Buy |
91
+17
| +23% | +$9.04K | ﹤0.01% | 5795 |
|
|
2017
Q2 | $44K | Sell |
74
-2,305
| -97% | -$1.02M | ﹤0.01% | 5749 |
|
|
2017
Q1 | $1.02M | Buy |
2,379
+2,198
| +1,214% | +$925K | ﹤0.01% | 3512 |
|
|
2016
Q4 | $93K | Sell |
181
-170
| -48% | -$99.3K | ﹤0.01% | 5348 |
|
|
2016
Q3 | $149K | Sell |
351
-9,540
| -96% | -$3.73M | ﹤0.01% | 4741 |
|
|
2016
Q2 | $4.15M | Buy |
+9,891
| New | +$4.15M | ﹤0.01% | 2109 |
|
Other funds holding RNAC
VCM
6CM
EAM
UBS Group's RNAC Position: Q1 2026 in Review
UBS Group increased its Cartesian Therapeutics (RNAC) stake by 103% in Q1 2026, buying an estimated $495K and bringing the position to 136,840 shares worth $842K. The position accounts for ﹤0.01% of the portfolio, ranked #5684.
UBS Group first reported a position in RNAC in Q2 2016 and has held it in 35 quarters since. The position peaked at $4.15M in Q2 2016. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- UBS Group held 136,840 shares of Cartesian Therapeutics worth $842K as of Q1 2026.
- UBS Group bought 69,499 Cartesian Therapeutics shares in Q1 2026, an estimated $495K.
- Cartesian Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5684 holding.
- UBS Group first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 35 quarters since.
- UBS Group's Cartesian Therapeutics position peaked at $4.15M in Q2 2016.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.